Quoted from http://www.cbc.ca/consumer/story/2011/01/17/multaq-heart-liver.html
Heart drug Multaq to be monitored in Canada
U.S. added warnings after liver damage reports
Last Updated: Monday, January 17, 2011 | 1:45 PM ET
CBC News
The heart drug Multaq continues to be approved for use in Canada, but Health Canada says reports of its connection to liver damage will be reviewed.
On Friday, the U.S. Food and Drug Administration added new warnings to the label of the Sanofi-Aventis drug after several reports that patients suffered liver damage.
Multaq was approved in July 2009 to treat atrial flutter and atrial fibrillation — irregular heart rhythms that can reduce blood flow and lead to stroke.
Liver toxicity is among the most common drug-related side-effects in a number of medication classes.
Health Canada says that in Canada the drug is not to be used by patients with severe liver problems. It says that should new safety information be identified, it will take appropriate action — including keeping health-care professionals and other Canadians informed.